We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
{\"0\":\"SOLV posted Q2 EPS of $1.69, beating estimates by 16.6% and rising 8.3% year over year.\",\"1\":\"SOLV\'\'s Q2 sales rose 3.9% to $2.16B, with MedSurg and HIS leading organic growth across all segments.\",\"2\":\"SOLV raised FY25 EPS guidance to $5.80-$5.95 and lifted organic sales growth view to 2-3%.\"}
Solventum (SOLV - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.69, which beat the Zacks Consensus Estimate of $1.45 by 16.6%. The bottom line gained 8.3% year over year.
GAAP EPS in the quarter was 51 cents, flat year over year.
Revenue Details
The company reported revenues of $2.16 billion, up 3.9% reportedly from the prior-year recorded number. Organically, sales were up 2.8%. The metric beat the Zacks Consensus Estimate by 1.9%. Organic sales growth was primarily driven by positive performance from all segments, primarily MedSurg and HIS.
Shares of the company were up 5% during after-hours trading on Aug. 7, following strong quarterly results. The stock has risen 8.9% so far this year against the industry’s decline of 8.6%. The S&P 500 Index has gained 7.7% in the same period.
Image Source: Zacks Investment Research
Segmental Details
MedSurg
Revenues from this segment totaled $1.23 billion, up 4.8% reportedly and up 3.9% organically year over year. Organic growth was driven by differentiated brands, new product launches and commercial restructuring efforts.
Dental Solutions
Revenues totaled $338 million, up 2.3% year over year reportedly and up 0.7% organically. The growth was driven by new product innovations and increased sales channel specialization.
HIS
Revenues from this segment amounted to $339 million, up 3.4% reportedly and 3.2% organically on a year-over-year basis. The growth was driven by partnership with Ensemble, a leading end-to-end provider of RCM services as well as its leadership position in AI-driven solutions for healthcare operation.
Purification and Filtration
Revenues from this segment amounted to $252 million, up 3.4% year over year reportedly and up 3.1% organically. Growth was driven by strong demand for bioprocessing solutions and expanded capacity for industrial business.
Margins
Adjusted gross profit was $1.21 billion, up 4.1% year over year. As a percentage of revenues, the adjusted gross margin was 56%, up approximately 20 bps from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $772 million, up 10.1% year over year.
Research and development expenses totaled $189 million, down 1.6% on a year-over-year basis.
Adjusted operating income totaled $474 million, up 10.2% year over year. As a percentage of revenues, the adjusted operating margin was 21.9%, up approximately 120 bps from the prior-year quarter’s figure.
Financial Position
Solventum exited the second quarter with cash, cash equivalents and investments of $492 million compared with $534 million in the previous quarter.
Total assets increased to $15.07 billion from $14.52 billion in the previous quarter.
2025 Guidance
Solventum raised its sales guidance for 2025. Solventum now expects organic sales growth of 2-3% (2.5-3.5% excluding ~50bps of SKU Exit impact), up from the previous guidance of 1.5-2.5%. The Zacks Consensus Estimate for the same is pegged at $8.43 billion.
SOLV now expects adjusted EPS to be in the band of $5.80-$5.95 (previously $5.45-$5.65). The Zacks Consensus Estimate for earnings is pinned at $5.58 per share.
Solventum Corporation Price, Consensus and EPS Surprise
Solventum exited the second quarter on a strong note, with both the top and bottom lines beating their respective Zacks Consensus Estimate. The organic growth at SOLV’s largest segment (in terms of revenues), MedSurg, looks promising. The trend is likely to continue in the upcoming quarters as well due to continued demand for its products. Strong adoption of 360 Encompass revenue cycle management is likely to aid sales growth for the HIS segment in the future.
SOLV is undergoing a three-phase restructuring program after its separation from 3M in 2023. Phase 1 is expected to be completed within 12-24 months, focusing on debt reduction, portfolio optimization and operational efficiency. These initiatives fuel the company’s long-term prospects.
SOLV’s Zacks Rank and Key Picks
Solventum currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank #1 (Strong Buy) at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
Key Takeaways
Solventum (SOLV - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.69, which beat the Zacks Consensus Estimate of $1.45 by 16.6%. The bottom line gained 8.3% year over year.
GAAP EPS in the quarter was 51 cents, flat year over year.
Revenue Details
The company reported revenues of $2.16 billion, up 3.9% reportedly from the prior-year recorded number. Organically, sales were up 2.8%. The metric beat the Zacks Consensus Estimate by 1.9%. Organic sales growth was primarily driven by positive performance from all segments, primarily MedSurg and HIS.
Shares of the company were up 5% during after-hours trading on Aug. 7, following strong quarterly results. The stock has risen 8.9% so far this year against the industry’s decline of 8.6%. The S&P 500 Index has gained 7.7% in the same period.
Image Source: Zacks Investment Research
Segmental Details
MedSurg
Revenues from this segment totaled $1.23 billion, up 4.8% reportedly and up 3.9% organically year over year. Organic growth was driven by differentiated brands, new product launches and commercial restructuring efforts.
Dental Solutions
Revenues totaled $338 million, up 2.3% year over year reportedly and up 0.7% organically. The growth was driven by new product innovations and increased sales channel specialization.
HIS
Revenues from this segment amounted to $339 million, up 3.4% reportedly and 3.2% organically on a year-over-year basis. The growth was driven by partnership with Ensemble, a leading end-to-end provider of RCM services as well as its leadership position in AI-driven solutions for healthcare operation.
Purification and Filtration
Revenues from this segment amounted to $252 million, up 3.4% year over year reportedly and up 3.1% organically. Growth was driven by strong demand for bioprocessing solutions and expanded capacity for industrial business.
Margins
Adjusted gross profit was $1.21 billion, up 4.1% year over year. As a percentage of revenues, the adjusted gross margin was 56%, up approximately 20 bps from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $772 million, up 10.1% year over year.
Research and development expenses totaled $189 million, down 1.6% on a year-over-year basis.
Adjusted operating income totaled $474 million, up 10.2% year over year. As a percentage of revenues, the adjusted operating margin was 21.9%, up approximately 120 bps from the prior-year quarter’s figure.
Financial Position
Solventum exited the second quarter with cash, cash equivalents and investments of $492 million compared with $534 million in the previous quarter.
Total assets increased to $15.07 billion from $14.52 billion in the previous quarter.
2025 Guidance
Solventum raised its sales guidance for 2025. Solventum now expects organic sales growth of 2-3% (2.5-3.5% excluding ~50bps of SKU Exit impact), up from the previous guidance of 1.5-2.5%. The Zacks Consensus Estimate for the same is pegged at $8.43 billion.
SOLV now expects adjusted EPS to be in the band of $5.80-$5.95 (previously $5.45-$5.65). The Zacks Consensus Estimate for earnings is pinned at $5.58 per share.
Solventum Corporation Price, Consensus and EPS Surprise
Solventum Corporation price-consensus-eps-surprise-chart | Solventum Corporation Quote
Our Take
Solventum exited the second quarter on a strong note, with both the top and bottom lines beating their respective Zacks Consensus Estimate. The organic growth at SOLV’s largest segment (in terms of revenues), MedSurg, looks promising. The trend is likely to continue in the upcoming quarters as well due to continued demand for its products. Strong adoption of 360 Encompass revenue cycle management is likely to aid sales growth for the HIS segment in the future.
SOLV is undergoing a three-phase restructuring program after its separation from 3M in 2023. Phase 1 is expected to be completed within 12-24 months, focusing on debt reduction, portfolio optimization and operational efficiency. These initiatives fuel the company’s long-term prospects.
SOLV’s Zacks Rank and Key Picks
Solventum currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank #1 (Strong Buy) at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.